The only neutral and antibody drugs in the world that can be used in the new crown's pre -exposure of the new crown landing Music City

Author:Kenji Bureau Time:2022.07.06

On July 5th, the official website of Hainan Free Trade Port Boao Le City International Medical Tourism Pilot Zone released news: The world's only neutral and antibody drug Evusheld, which can be used in the new crown pre -exposed prevention.

This drug is Astraikon's product. It is currently approved in the United States, the European Union and other places. It is suitable for adults and more than 40 kg of young new crown virus before exposure.

EVUSHELD is a combination of antibody combination, which is composed of Tengovirab and Sigavirke. According to the real "living" virus data of the University of Washington Medical School, EVUSHELD has strong neutralization of the main epidemic plants including Omikon.

According to the advanced area of the Boao Le City, EVUSHELD is preferentially suitable for the prevention of new coronal virus infection of immune function damage or low immunity, such as tumor patients, organ transplant patients, dialysis patients who are undergoing chemotherapy. At the same time, EVUSHELD can also be used for people with poor effects using new crown vaccines and additional protection of vaccines.

According to relevant regulations, Boao Lecheng is a pilot area for imported medical products. The approved products are limited to the use of relevant hospitals in Boao area, and are not the same as the "import listing" that can be stored in the country.

At present, EVUSHELD can be used in Ruijin Hainan Hospital and Super Hospital in Boao City.

After the news was issued, Rykang Pharmaceuticals stated simultaneously: Long -term cooperation with Astraikon should be able to get Evusheld Mainland China Agent, but the company is not the only agent and is expected to find many agents. Affected by this news, Ruikang Pharmaceutical's stock price daily limit on July 6.

Writing | Nicotinamide

Edit ｜ Jiang Yun Jia Ting

Operation ｜ Valley

Illustration | Visual China

- END -